C E Ford1, G Punnia-Moorthy2, C E Henry2, E Llamosas2, S Nixdorf3, J Olivier4, R Caduff5, R L Ward2, V Heinzelmann-Schwarz6. 1. Wnt Signalling & Metastasis Group, Lowy Cancer Research Centre and Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Australia. Electronic address: caroline.ford@unsw.edu.au. 2. Wnt Signalling & Metastasis Group, Lowy Cancer Research Centre and Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Australia. 3. Gynaecological Cancer Group, Lowy Cancer Research Centre and Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Australia. 4. School of Mathematics and Statistics, Faculty of Science, University of New South Wales, Australia. 5. Department of Clinical Pathology, University Hospital Zurich, Zurich, Switzerland. 6. Gynaecological Cancer Group, Lowy Cancer Research Centre and Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Australia; Women's Hospital, University Hospital Basel, Basel, Switzerland.
Abstract
OBJECTIVE: Aberrant Wnt signalling has previously been associated with gynaecological cancers, and the aim of this study was to investigate the expression of Wnt5a in epithelial ovarian cancer, and clarify its role in activating or inhibiting β-catenin dependent and independent Wnt signalling pathways. METHOD: Wnt5a expression was investigated in a large cohort of epithelial ovarian cancer patient samples using immunohistochemistry and correlated with clinicopathological variables. Wnt5a function was investigated in vitro in ovarian cell lines. RESULTS: Wnt5a expression was found to be upregulated in all major subtypes (serous, endometrioid, clear cell and mucinous) of epithelial ovarian cancer compared to borderline tumours and benign controls. Treatment of ovarian surface epithelial cells with recombinant Wnt5a decreased cell adhesion and was associated with increased epithelial to mesenchymal transition (EMT). In addition, downstream targets of β-catenin dependent Wnt signalling were inhibited, and β-catenin independent targets increased following Wnt5a upregulation. Knockdown of Wnt5a in ovarian cancer cells was associated with a mesenchymal to epithelial transition (MET), but had no significant effect on cell migration or proliferation. CONCLUSION: This study adds to the increasing evidence that Wnt signalling may play an important role in ovarian cancer development. Utilising an unparalleled large cohort of 623 patients, Wnt5a protein expression was shown to be significantly higher in ovarian cancer patients when compared to benign and borderline ovarian tumours and healthy control patients. In addition, we have utilised in vitro models to show for the first time in ovarian cancer that Wnt5a driven non-canonical pathways can alter epithelial to mesenchymal transition (EMT). Crown
OBJECTIVE: Aberrant Wnt signalling has previously been associated with gynaecological cancers, and the aim of this study was to investigate the expression of Wnt5a in epithelial ovarian cancer, and clarify its role in activating or inhibiting β-catenin dependent and independent Wnt signalling pathways. METHOD:Wnt5a expression was investigated in a large cohort of epithelial ovarian cancerpatient samples using immunohistochemistry and correlated with clinicopathological variables. Wnt5a function was investigated in vitro in ovarian cell lines. RESULTS:Wnt5a expression was found to be upregulated in all major subtypes (serous, endometrioid, clear cell and mucinous) of epithelial ovarian cancer compared to borderline tumours and benign controls. Treatment of ovarian surface epithelial cells with recombinant Wnt5a decreased cell adhesion and was associated with increased epithelial to mesenchymal transition (EMT). In addition, downstream targets of β-catenin dependent Wnt signalling were inhibited, and β-catenin independent targets increased following Wnt5a upregulation. Knockdown of Wnt5a in ovarian cancer cells was associated with a mesenchymal to epithelial transition (MET), but had no significant effect on cell migration or proliferation. CONCLUSION: This study adds to the increasing evidence that Wnt signalling may play an important role in ovarian cancer development. Utilising an unparalleled large cohort of 623 patients, Wnt5a protein expression was shown to be significantly higher in ovarian cancerpatients when compared to benign and borderline ovarian tumours and healthy control patients. In addition, we have utilised in vitro models to show for the first time in ovarian cancer that Wnt5a driven non-canonical pathways can alter epithelial to mesenchymal transition (EMT). Crown
Authors: Kathleen N Moore; Camille C Gunderson; Paul Sabbatini; D Scott McMeekin; Gina Mantia-Smaldone; Robert A Burger; Mark A Morgan; Ann M Kapoun; Rainer Karl Brachmann; Robert Stagg; Azeez Farooki; Roisin E O'Cearbhaill Journal: Gynecol Oncol Date: 2019-06-04 Impact factor: 5.482
Authors: Marwa Asem; Allison M Young; Carlysa Oyama; Alejandro Claure De La Zerda; Yueying Liu; Jing Yang; Tyvette S Hilliard; Jeffery Johnson; Elizabeth I Harper; Ian Guldner; Siyuan Zhang; Toni Page-Mayberry; William J Kaliney; M Sharon Stack Journal: Cancer Res Date: 2020-01-13 Impact factor: 12.701
Authors: Shu Ning; Chengfei Liu; Wei Lou; Joy C Yang; Alan P Lombard; Leandro S D'Abronzo; Neelu Batra; Ai-Ming Yu; Amy R Leslie; Masuda Sharifi; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2022-10-07 Impact factor: 6.009
Authors: Michael W Susman; Edith P Karuna; Ryan C Kunz; Taranjit S Gujral; Andrea V Cantú; Shannon S Choi; Brigette Y Jong; Kyoko Okada; Michael K Scales; Jennie Hum; Linda S Hu; Marc W Kirschner; Ryuichi Nishinakamura; Soichiro Yamada; Diana J Laird; Li-En Jao; Steven P Gygi; Michael E Greenberg; Hsin-Yi Henry Ho Journal: Elife Date: 2017-09-08 Impact factor: 8.140
Authors: Michael P Endsley; Georgette Moyle-Heyrman; Subbulakshmi Karthikeyan; Daniel D Lantvit; David A Davis; Jian-Jun Wei; Joanna E Burdette Journal: Front Oncol Date: 2015-07-17 Impact factor: 6.244